Menu
Search
|

Menu

Close
X

Halozyme Therapeutics Inc HALO.OQ (NASDAQ Stock Exchange Global Select Market)

16.81 USD
+0.20 (+1.20%)
As of 3:59 PM EST
chart
Previous Close 16.61
Open 16.61
Volume 376,540
3m Avg Volume 289,202
Today’s High 16.98
Today’s Low 15.87
52 Week High 21.47
52 Week Low 13.24
Shares Outstanding (mil) 144.56
Market Capitalization (mil) 2,401.10
Forward P/E 62.07
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.64 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
92
FY17
317
FY16
147
EPS (USD)
FY18
-0.545
FY17
0.347
FY16
-0.805
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
62.07
35.95
Price to Sales (TTM)
vs sector
8.54
9.98
Price to Book (MRQ)
vs sector
10.01
4.53
Price to Cash Flow (TTM)
vs sector
50.06
26.23
Total Debt to Equity (MRQ)
vs sector
61.09
16.61
LT Debt to Equity (MRQ)
vs sector
24.17
13.07
Return on Investment (TTM)
vs sector
16.30
12.64
Return on Equity (TTM)
vs sector
29.27
13.82

EXECUTIVE LEADERSHIP

Connie Matsui
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Helen Torley
President, Chief Executive Officer, Director, Since 2014
Salary: $671,000.00
Bonus: $699,115.00
Laurie Stelzer
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $452,000.00
Bonus: $282,563.00
Harry Leonhardt
Senior Vice President, Chief Compliance Officer, General Counsel, Since 2015
Salary: $425,000.00
Bonus: $242,582.00
Athena Countouriotis
Senior Vice President, Chief Medical Officer, Since 2015
Salary: $236,493.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11388 Sorrento Valley Rd
SAN DIEGO   CA   92121-1345

Phone: +1858.7948889

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

SPONSORED STORIES